Dir of Med Affairs at Labcorp Oncology; Gyn Onc; Duke adjunct. Pet mom to 🐶🐶🐱🦔🐭🐓🐝; passionate about pollination, gardening & piano. Opinions are mine.
Joined March 2017
- Tweets 723
- Following 499
- Followers 1,039
- Likes 1,722
185 Photos and videos
Rebecca Previs retweeted
7 Jun 2023
Comprehensive Genomic Profiling: A Required Tool for Precision Oncology @ASCO @ASCOPost @OncoAlert #ASCO23 @weoncologists
ascopubs.org/doi/10.1200/ADN…
23
68
32,826
Rebecca Previs retweeted
11 May 2023
One more week until our live Ask the Expert Q&A with @Labcorp's @BeccaPrevisMD! Join us to learn how #personalized #medicine is transforming #breastcancer treatment and explore emerging targeted therapies for HER2-low breast cancer subtypes: us02web.zoom.us/webinar/regi…
ALT Outcomes4Me is hosting an Ask the Expert webinar series on the topic of "What is HER2-low and why should I get tested?" Tile showcases graphics, text, and Dr. Previs's headshot.
2
4
421
Rebecca Previs retweeted
27 Apr 2023
Want to learn more about HER2-low breast cancer? Please tune into this webinar by my amazing colleague and oncologist, Dr. @BeccaPrevisMD as she leads important discussions around HER2-low breast cancer! 🙌🏻
27 Apr 2023
Join us for our upcoming Ask the Expert Q&A with @BeccaPrevisMD from @Labcorp where she'll discuss how personalized medicine is transforming breast cancer treatment and emerging targeted therapies for HER2-low breast cancer subtypes.
us02web.zoom.us/webinar/regi…
1
1
417
Rebecca Previs retweeted
27 Mar 2023
👏🙌NRG GY018!! We did it - improved progression free survival in MMRd AND MMRp #EndometrialCancer. Standard of care == CHANGED! #SGOMtg #gyncsm #ImmunoOnc Congrats to @NRGonc
5
88
269
40,044
27 Mar 2023
Check out @ElizabethABloom’s work today at #SGOMtg. She reports a molecular analysis of a retrospective cohort of patients with endometrial intraepithelial hyperplasia. 5% were dMMR; 4% were p53abn. @dukeobgyn #Previslab @KC_Strickland @pammiepeters @janicewon_ 🧪🔬👩🔬🧬
3
14
748
26 Mar 2023
Mentoring is one of life’s greatest privileges—and it’s not about creating clones but giving the space for each to create themselves and their own authentic paths. Couldn’t be prouder of @pammiepeters and @ElizabethABloom. ⭐️ 👩🔬🔬🧬🧪#WomenInSTEM #sgomtg #PatientsPurposeProgress
2
30
1,098
26 Mar 2023
Checkpoint inhibition has had limited efficacy in high grade epithelial cancer. So proud of @pammiepeters and her work evaluating MEM-288, a novel oncolytic adenovirus, demonstrating efficacy and generating a systemic immune response. #SGOMtg @dukeobgyn #PatientsPurposeProgress
5
15
3,513
Rebecca Previs retweeted
26 Mar 2023
Our fellow Pamela Peters discussing her work on MEM-288 under mentor @BeccaPrevisMD proud of her work to improve the understanding of ovarian cancer immune response @dukeobgyn
3
7
1,001
25 Mar 2023
The data are in! Cryocompression therapy works during chemo and prevents subjective neuropathy in patients with gyn cancers. Congrats @MKMontesDeOca @LHavrilesky and @dukeobgyn team. #SGOMtg #PatientsPurposeProgress
7
16
2,666
25 Mar 2023
Thank you @Stigetta and @womenofteal for being a voice and a light. We are grateful for your advocacy, leadership, and reminding us of our purpose. #SGOMtg #PatientsPurposeProgress
6
10
807
Rebecca Previs retweeted
Standing room only for Dr. Britta Weigelt’s discussion of circulating tumor DNA! #SGO2023 @MSKPathology @SGO_org
4
23
1,521
25 Mar 2023
Congrats to @DukeMedSchool’s @LindaM_Zambrano and her important work highlighting funding to lethality scores in patients with cancer. Despite its increase in mortality, #uterinecancer remains underfunded. This work informs policy change, advocacy and equitable funding. #sgomtg
1
6
15
1,569
25 Mar 2023
1
135
11 Dec 2022
10 Dec 2022
Thanks to everyone who attended our @Labcorp Case Study presentation where we reviewed the clinical, morphologic, cytogenetic, and #molecular characteristics of a case with a TP53 biallelic alteration. #ASH22 @ASH_hematology
1
7 Dec 2022
If you will be at the #ASH22 meeting next week, check out my @Labcorp teammate, @ESeversonMDPhD's presentation. 💜 the #ASHaiku! @ASH_hematology
7 Dec 2022
Getting ready for the #ASH22 meeting with my #ASHaiku:
ASH workshop with me
December 10th, New Orleans
Hemepath with @Labcorp
@ASH_hematology
2
7 Dec 2022
We analyzed ClinicalTrials,gov and found <10% of trials enrolling patients with gyn cancers report racial/ethnicity. We need diversity transparency in enrollment. bit.ly/3Fdz49y @tomi_akinyemiju @MKMontesDeOca @BenPeipert @dukeobgyn @DukeCancer @Labcorp @ESeversonMDPhD
4
2
Rebecca Previs retweeted
15 Nov 2022
Healthcare Access Dimensions and Guideline-Concordant #OvarianCancer Treatment: SEER-Medicare Analysis of the ORCHiD Study: jnccn.org/view/journals/jncc…
@MKMontesdeOca @BeccaPrevisMD @anjaligupta1680 @MariaPisu1 @MLiangMD @Kevin_C_Ward @AndrewBerchuck @tomi_akinyemiju
#hsronc #GynCSM
7
10
11 Nov 2022
Congrats @MKMontesDeOca and Dr. Tomi Akinyemiju!
10 Nov 2022
Study finds patient’s race affects ovarian cancer care. Read more: ↙️ corporate.dukehealth.org//ne…
1
Rebecca Previs retweeted
5 Nov 2022
We performed CGP on 3288 samples using @OmniSeqInsight’s NGS assay. We identified 16 NRG1 fusions – with an incidence of 0.4%. RNA sequencing increases the detection rate for NRG1 fusions and offers therapy options for patients. Visit our @Labcorp poster #AMPath22 #AMPlifier
2
4
Rebecca Previs retweeted
5 Nov 2022
Check out poster #ST028 @AMPath today. @PGDx presents their validation study on plasma focus, an #NGS assay designed for solid tumor profiling from cfDNA. This assay reports SNVs/indels for 33 genes, amplifications in 8 genes, gene fusions in 5 genes and MSI. #AMPath22 #AMPlifier
2
6